Surgical Management of the Axilla in Patients Presenting with Clinically Node Positive Hormone Receptor Positive, HER2 Negative (HR+/HER2-) Breast Cancer

被引：0
|
作者：
Jasper, Jacob [1 ]
Kantor, Olga [2 ]
Dorninici, Laura [3 ]
Nakhlis, Faina [4 ]
Ogayo, Esther [5 ]
Nimbkar, Suniti [6 ]
Kurt, Busem Binbogct [5 ]
King, Tari [7 ]
Mittendorf, Elizabeth [7 ]
机构：
[1] Tufts Univ, Medford, MA USA
[2] Brigham & Womens Hosp, Boston, MA USA
[3] Brigham & Womens Faulkner Hosp, Dana Farber Canc Inst, Boston, MA USA
[4] Brigham & Womens Hosp, Boston, MA USA
[5] Dana Farber Canc Inst, Boston, MA USA
[6] Dana Farber Brigham Canc Ctr, South Shore Hosp clin, Boston, MA USA
[7] Dana Farber Canc Inst, Brigham & Womens Hosp, Boston, MA USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2024年 / 31卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
E44
引用
收藏
页码：S101 / S101
页数：1
相关论文
共 50 条
  • [1] COMPARISON OF HER2 mRNA PCR LEVELS AND IMMUNOHISTOCHEMISTRY (IHC) IN HORMONE RECEPTOR POSITIVE (HR+)/HER2 NEGATIVE (HER2-) EARLY BREAST CANCER
    Tejerina-Peces, Julia
    Amann-Arevalo, Marta
    Ballestin, Pablo
    Gonzalez-Diez, Beatriz
    Paz-Cabezas, Mateo
    Pascual, Alejandro
    de Luna, Alicia
    Garcia-Barberan, Vanesa
    Lopez de Sa, Alfonso
    Garcia-Saenz, Jose Angel
    Moreno, Fernando
    CANCER RESEARCH, 2024, 84 (09)
  • [2] A phase 2 study of abemaciclib plus pembrolizumab for patients with hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC)
    Rugo, H.
    Tolaney, S.
    Dickler, M.
    Kabos, P.
    Ho, C-L
    Wildiers, H.
    Jerusalem, G.
    Ales-Martinez, J. E.
    Hossain, A.
    Johnston, E.
    Gianni, L.
    CANCER RESEARCH, 2017, 77
  • [3] A phase 1 study of abemaciclib and niraparib as neoadjuvant therapy in hormone receptor positive (HR+) HER2 negative (HER2-) breast cancer
    Li, Allen
    Naik, Arpana
    Johnson, Nathalie
    Goodyear, Shaun
    Johnson, Brett
    Park, Byung
    Corless, Christopher
    Gray, Joe
    Mills, Gordon
    Mitri, Zahi
    CANCER RESEARCH, 2021, 81 (04)
  • [4] Development and validation of RSClin N plus tool for hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive breast cancer
    Pusztai, Lajos
    Hoag, Jess R.
    Albain, Kathy S.
    Barlow, William E.
    Stemmer, Salomon M.
    Meisner, Allison
    Hortobagyi, Gabriel N.
    Shak, Steven
    Hayes, Daniel F.
    Rae, James M.
    Baehner, Frederick
    Sharma, Priyanka
    Kalinsky, Kevin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] An Indirect Treatment Comparison of the Efficacy of Everolimus (Afinitor®) and Fulvestrant for the Treatment of Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Advanced or Metastatic Breast Cancer
    Chandiwana, D.
    Vieira, J.
    Granville, J.
    McCool, R.
    Fleetwood, K.
    VALUE IN HEALTH, 2013, 16 (07) : A393 - A394
  • [6] The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?
    Aapro, Matti
    De Laurentiis, Michelino
    Rea, Dan
    Bargallo Rocha, Juan Enrique
    Elizalde, Roberto
    Landherr, Laszlo
    Linderholm, Barbro
    Mamounas, Eleftherios
    Markopoulos, Christos
    Neven, Patrick
    Petrovsky, Alexander
    Rouzier, Roman
    Smit, Vincent
    Svedman, Christer
    Schneider, Daniel
    Thomssen, Christoph
    Martin, Miguel
    BREAST, 2017, 33 : 191 - 199
  • [7] Impact of gene expression profile testing for lymph node positive (LN plus ), hormone receptor positive (HR+), HER2 negative (HER2-) breast cancer (BC) patients on the use of adjuvant chemotherapy in a large community cancer center
    Kalmadi, Nisha Rao
    Brown, Andrew
    Sharma, Manas
    Shtivelband, Mikhail
    Rifkind, Joshua
    Kalmadi, Sujith
    Bagai, Rajesh
    Ho, Emily
    Clark, Patricia
    Kellogg, Christopher
    Khanuja, Parvinderjit
    CANCER RESEARCH, 2022, 82 (04)
  • [8] Disease features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor positive (HR+), HER2 negative (HER2-) metastatic breast cancer (MBC) patients
    Wang, Jinhao
    Liu, Yaxin
    Shao, Bin
    Dong, Hang
    Zheng, Tiantian
    Du, Pan
    Jia, Shidong
    King, Bonnie
    Wang, Jing
    Liu, Xiaoran
    Li, Huiping
    CANCER RESEARCH, 2023, 83 (05)
  • [9] Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
    Engel-Nitz, Nicole M.
    Johnson, Mary G.
    Johnson, Michael P.
    Cha-Silva, Ashley S.
    Kurosky, Samantha K.
    Liu, Xianchen
    PATIENT PREFERENCE AND ADHERENCE, 2023, 17 : 1049 - 1062
  • [10] Treatment of Advanced Hormone Receptor-Positive (HR+) HER2-negative Breast Cancer
    Ditsch, Nina
    Schmidt, Marcus
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2019, 79 (12) : 1328 - 1335
12345